666 related articles for article (PubMed ID: 24927239)
1. FDG-PET and amyloid-PET imaging: the diverging paths.
Perani D
Curr Opin Neurol; 2014 Aug; 27(4):405-13. PubMed ID: 24927239
[TBL] [Abstract][Full Text] [Related]
2. Molecular imaging of dementia.
Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.
Shokouhi S; Campbell D; Brill AB; Gwirtsman HE;
Brain Pathol; 2016 Sep; 26(5):664-71. PubMed ID: 27327527
[TBL] [Abstract][Full Text] [Related]
4. PET of brain amyloid and tau in mild cognitive impairment.
Small GW; Kepe V; Ercoli LM; Siddarth P; Bookheimer SY; Miller KJ; Lavretsky H; Burggren AC; Cole GM; Vinters HV; Thompson PM; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
N Engl J Med; 2006 Dec; 355(25):2652-63. PubMed ID: 17182990
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
6. In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.
Dronse J; Fliessbach K; Bischof GN; von Reutern B; Faber J; Hammes J; Kuhnert G; Neumaier B; Onur OA; Kukolja J; van Eimeren T; Jessen F; Fink GR; Klockgether T; Drzezga A
J Alzheimers Dis; 2017; 55(2):465-471. PubMed ID: 27802224
[TBL] [Abstract][Full Text] [Related]
7. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
Watanabe H
Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
[TBL] [Abstract][Full Text] [Related]
8. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
9. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
Villemagne VL; Rowe CC
J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
[TBL] [Abstract][Full Text] [Related]
10. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
[TBL] [Abstract][Full Text] [Related]
11. [Amyloid-plaque imaging of the brain using PET].
Ossenkoppele R; Tolboom N; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN
Ned Tijdschr Geneeskd; 2011; 155():A2981. PubMed ID: 21586182
[TBL] [Abstract][Full Text] [Related]
12. Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.
Parent MJ; Zimmer ER; Shin M; Kang MS; Fonov VS; Mathieu A; Aliaga A; Kostikov A; Do Carmo S; Dea D; Poirier J; Soucy JP; Gauthier S; Cuello AC; Rosa-Neto P
J Neurosci; 2017 Dec; 37(50):12263-12271. PubMed ID: 29097597
[TBL] [Abstract][Full Text] [Related]
13. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.
Rodriguez-Vieitez E; Kumar A; Malarte ML; Ioannou K; Rocha FM; Chiotis K
Methods Mol Biol; 2024; 2785():195-218. PubMed ID: 38427196
[TBL] [Abstract][Full Text] [Related]
14. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.
Pascoal TA; Mathotaarachchi S; Shin M; Park AY; Mohades S; Benedet AL; Kang MS; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P;
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):1021-1030. PubMed ID: 29396637
[TBL] [Abstract][Full Text] [Related]
15. Amyloid imaging: Past, present and future perspectives.
Villemagne VL
Ageing Res Rev; 2016 Sep; 30():95-106. PubMed ID: 26827784
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
Koychev I; Hofer M; Friedman N
J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
[TBL] [Abstract][Full Text] [Related]
18. Amyloid imaging.
Villemagne VL; Rowe CC
Int Psychogeriatr; 2011 Sep; 23 Suppl 2():S41-9. PubMed ID: 21729418
[TBL] [Abstract][Full Text] [Related]
19. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease.
Scheltens P; Blennow K; Breteler MM; de Strooper B; Frisoni GB; Salloway S; Van der Flier WM
Lancet; 2016 Jul; 388(10043):505-17. PubMed ID: 26921134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
